Companies › Schrödinger
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SGR-3515 | – | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| SGR-1505 | – | Phase 1 | Mature B-Cell Neoplasm | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06463340 | SGR-3515 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT05544019 | SGR-1505 | Phase 1 | Mature B-Cell Neoplasm | Oncology | Nov 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.